

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence














